LYRICA CR (pregabalin) by Viatris is 2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. First approved in 2017.
Drug data last refreshed 23h ago · AI intelligence enriched Yesterday
LYRICA CR is an extended-release oral formulation of pregabalin, a small-molecule analog of gamma-aminobutyric acid (GABA) that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. It is indicated for neuropathic pain conditions and works by reducing calcium-dependent release of pro-nociceptive neurotransmitters in the spinal cord and modulating descending pain pathways. The mechanism does not involve direct GABA receptor binding, benzodiazepine activity, or opioid receptor engagement.
Product is approaching loss of exclusivity with modest Part D utilization; brand team focus will shift toward lifecycle extension and managed market strategies within 6-12 months.
2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Worked on LYRICA CR at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants
Efficacy and Safety of Pregabalin/Tizanidine vs. Pregabalin in Patients With Fibromyalgia
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject
Pharmacodynamic Study of 300mg Pregabalin vs Placebo in Healthy Male Adults
Effect of Pregabalin on Shoulder Pain in Patients With Central Sensitization After Arthroscopic Rotator Cuff Repair
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
Working on LYRICA CR at this stage of its lifecycle offers limited upside for ambitious career growth; the product is transitioning from a mature branded position into generic competition. Opportunities are primarily in defensive strategy, market access, and managed care—roles suited to professionals with expertise in portfolio optimization and post-LOE product stewardship rather than new product launch or expansion.